Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bioeconomy goes hand in hand with cancer research in a joint project between UPM and FIMM

(UPM, Helsinki, 12 May 2016 at 10:00 EET) - The Institute for Molecular Medicine Finland (FIMM), at the University of Helsinki and UPM Biochemicals have started a joint research project with the purpose of investigating the applicability of UPM's new cellulose-based gel material for cancer research. The project focuses on growing cancer cells on a three-dimensional culture using UPM's new biomaterial and studying the drug responses of the cancer cells. This exciting research project brings together two growth areas: bioeconomy and personalised medicine. "One of the key challenges in

Subscription Period for Rights Issue in Oncology Venture Sweden AB Begins Today

Today, May 12, 2016, is the first day of the subscription period for rights issue in Oncology Venture Sweden AB (OV). The rights issue may also be signed by the public. Subscription period runs through May 26, 2016. Should the rights issue be fully subscribed, it will raise a capital of 20.7 million SEK before issuing costs. Beforehand, the company has agreed on subscription commitments amounting to approximately 13.1 million SEK, which equals about 64% of the rights issue’s total volume. Prospect, teaser and application form can be downloaded at the respective websites of Oncology Venture (

INTERIM REPORT JANUARY - MARCH 2016

FIRST QUARTER · Net sales amounted to MSEK 82.3 (0.4) · Earnings before depreciation were MSEK 9.3 (-14.9) · Earnings per share amounted to SEK 0.06 (-0.42) · Cash and cash equivalents at period end amounted to MSEK 11.2 (32.2) · The name of the Group was changed to Karo Pharma to better re-flect current operations SIGNIFICANT EVENTS AFTER PERIOD END · Two share issues totaling MSEK 280 were carried out. The issues, which were oversubscribed by 210 per cent, were completed after period end, hence not being reflected in the cash position. Executive Chairman Anders

TORM announces new distribution policy

The combination of the 2015 Restructuring and the strong prevailing product tanker freight rates has given TORM plc ("TORM") considerable strategic and financial flexibility. Therefore, TORM's Board of Directors has today approved a new distribution policy that will allow investors to benefit from the earnings while enabling TORM to selectively invest in the fleet. The distribution policy opens for dividends and/or share repurchases.TORM anticipates having one fixed distribution in September 2016 of USD 25.0m. With semi-annual distributions, this corresponds to an annualized dividend of

Publication of TORM A/S' first quarter 2016 report

"In the first quarter of 2016, the product tanker market continued at profitable levels. TORM's operational platform proved its strength again and delivered average freight rates of almost 20,000 USD/day, which is in line with the level seen in the previous quarter despite a generally softer underlying market," says Executive Director Jacob Meldgaard and adds, "the strong operational cash flow has solidified our financial position further and provides strategic flexibility as well as enables a distribution policy."In the first quarter of 2016, TORM realized an EBITDA of USD 70m and a

Report from Cinnober’s Annual General Meeting 2016

Cinnober Financial Technology held its annual general meeting on Wednesday 11th of May under the chairmanship of attorney at law Thomas Nygren. The meeting took the following decisions, among others. · The income statement and balance sheet were approved for the parent company and the group. · The Board's proposal for distribution of profits was approved, which meant dividend payment in an amount of SEK 2 per share, in total SEK 13,098,240. The record day was determined to be 13th of May 2016. · The Board and the CEO were discharged from liability for the fiscal year 2015. ·

Interim report, January-March 2016

First quarter– January-March 2016 · No sales were recognised. · The operating loss totalled SEK -1,856 thousand (-1,791), consisting primarily of employee benefit expenses and other external costs. · Loss after tax was SEK -4,073 thousand (-2,827), corresponding to SEK -0.07 per share (-0.10). · Investments in exploration and evaluation assets totalled SEK 1,639 thousand (3,936).Key events during the quarter · On 26 January 2016, an extraordinary general meeting approved the directed issue proposed by the board in December 2015. The issue was directed to a small number of

Cherry Interim Report 1 2016, 1 January- 31 March 2016

Highlights First quarter: 86 percent growth in revenue and a positive EBITDA of MSEK 25.6 · Group revenue increased by 86 percent to MSEK 177.3 (95.3). Online makes up 78 percent (63) of the group revenue. · Profitability improved considerably and EBITDA amounted to MSEK 25.6 (-4.5). EBIT amounted to MSEK 17.4 (-8.9). · The result after tax was MSEK 17.5 (-11.8), equivalent to SEK 0.80 (-0.88) per share after dilution and minority interests. · Online Gaming grew by 118 percent and EBITDA amounted to MSEK 16.5 (-5.7). · Yggdrasil Gaming grew by 519 percent and EBITDA

20.7 percent EBITDA earnings growth in the quarter

January – March 2016 Sales amounted to SEK 395.1 million (400.8), a decrease of 1.4 percent before adjustments for acquired and divested businesses. Adjusted for the acquisition of Drew Tech and the divestment of Opus Equipment the revenue growth amounted to 4.1 percent. Operating profit before depreciation (EBITDA) amounted to SEK 61.4 million (50.9), corresponding to an EBITDA margin of 15.5 percent (12.7). Cash flow from operating activities amounted to SEK 9.0 million (30.6). Net financial income/expense include foreign exchange differences of SEK -8.0 million (54.2).

Hansa Medical appoints Henk Doude van Troostwijk as Vice President, Commercial Operations

Hansa Medical AB (publ) announced today the appointment of Henk Doude van Troostwijk as Vice President, Commercial Operations to strengthen its management team.Henk´s key focus will be on the company’s commercial assessments of its lead project IdeS, including market access, pricing and re-imbursement aspects. IdeS is now in Phase II clinical development focused on kidney transplantation in sensitized patients. “We are very excited that Henk will engage in Hansa Medical, as we now start to prepare our commercialization strategy for IdeS”, said Göran Arvidson, President and CEO of Hansa

Vitec Software Group AB: Bulletin from AGM 2016

AGM of Vitec Software Group AB (publ) was held on May 11 2016 in Umeå. DividendThe proposed dividend of 90 cents per share was approved by the AGM. The record date for the dividend is Friday, May 13 2016. Payment from Euroclear Sweden AB is expected Wednesday, May 18th, 2016. Adoption of income statement and balance sheetThe AGM adopted the income statement and balance sheet for the Parent Company and the consolidated income statement and consolidated balance sheet for 2015. DischargeBoard members and the President were discharged from liability for the financial year 2015.

Selvaag Bolig ASA: Q1 2016: Invitation to presentation of first quarter 2016 results

Selvaag Bolig ASA will publish its first quarter 2016 results on Thursday 19 May at 07:00 am CET. The quarterly report and the presentation materials will be available on the company's website, www.selvaagboligasa.no/en and www.newsweb.no, as well as news wires. CEO Baard Schumann and CFO Sverre Molvik will present the company's results at 08:30 am CET at Hotel Continental, Stortingsgaten 24-26 in Oslo. A light breakfast will be served from 08:00. Selvaag Bolig's board of directors will be present and available for questions before and after the presentation. The presentation will

Hexagon Composites ASA: Results for the first quarter 2016

In the first quarter 2016 Hexagon Composites generated NOK 291.6 (401.6) million in operating income and made an operating profit before depreciation (EBITDA) of NOK 18.6 (52.9) million. Operating profit (EBIT) was NOK 3.2 (39.5) million and profit/loss before tax came to NOK -2.6 (53.3) million.Operating results in the first quarter were impacted positively by a 17% growth in revenues within the Low-Pressure Cylinders segment versus the same period last year. However weak sales volumes for Mobile Pipeline[TM] solutions has hampered overall profitability for the Group, within the High-

Finnair’s strategy review: Finnair to accelerate its growth

Finnair Plc                            Stock Exchange Release                           12 May 2016 at 9:05 am EET  As a part of its annual strategy review, Finnair's Board of Directors has defined the focus areas for 2016–2018 in order to achieve the company’s strategic objectives. These are: · Profitable growth – Finnair seeks to grow slightly faster than its previous targets and gain market share. · Customer experience – the Company is developing its customer service, aligned with its vision of a Nordic customer experience. · People experience – Finnair is focusing on human

Etrion Releases First Quarter 2016 Results

May 12, 2016, Geneva, Switzerland – Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), a solar independent power producer, today released its condensed consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the three months ended March 31, 2016. Operational Highlights · Development: Advanced the backlog of three projects in Japan for a total capacity of 76 megawatts (“MW”). Management expects to reach financial close for these backlog projects within the second half of 2016. The Company is advancing the development

Attendo first quarter report 2016:  Demand for own operations and high quality gave stable growth and margins

Attendo is showing stable growth and profits for the first quarter 2016, driven primarily by strong demand for own operations. The margin was in line with last year, despite unfavourable seasonal effect. Progress in Attendo’s quality work contributed to important contract wins during the quarter.Comments by Henrik Borelius, CEO:“The quarter shows stable growth and profits due to continued strong development in own operations. The margin was in line with the same quarter last year, despite the negative seasonal effect and the start-up of several new units. During the quarter Attendo won

SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US

SELUMETINIB granted Orphan Drug Designation in the US for ADJUVANT treatment of Differentiated thyroid cancer AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the investigational MEK 1/2 inhibitor, selumetinib (AZD6244, ARRY-142886) for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC). DTC is diagnosed in approximately 60,000 people in the US each year,1 and radioactive iodine (RAI) is recommended for those with known/suspected metastases at diagnosis and those at high risk of

D. Carnegie & Co included in two new indices – the Nasdaq Nordic VINX Benchmark Index and the EPRA European Index

D. Carnegie & Co (publ) - listed on Nasdaq Stockholm – has been included in the NASDAQ Nordic VINX Benchmark Index as of 1 June this year. The VINX Benchmark Index include the largest and most actively traded stocks on Nordic Exchanges. The weight in the index is based on the portion of the shares available for trading, ie. the so called free float.D. Carnegie Co's share has recently been included in the European Public Real Estate Association EPRA Index for European property companies. In order to be included in the EPRA indices a certain free float is required, as is a sufficient

Finnair Group interim report 1 January – 31 March 2016

Finnair Plc                            Stock Exchange Release                            12 May 2016 at 9:00 am EET  Comparable operating result improved by 13 million euros in the seasonally weakest quarter January–March 2016 · Revenue grew by 2.9% year-on-year to 536.4 million euros (521.3). · Comparable operating result was -15.3 million euros (-28.4). · Comparable EBITDAR was 36.4 million euros (19.2). · Net cash flow from operating activities stood at 10.4 million euros (13.0), and net cash flow from investing activities totalled -247.3 million euros (142.8). ·

Strong net collections from recent acquisitions

Highlights first quarter 2016- Net collections increased by 39% to EUR 7.9M (Q1 2015: EUR 5.7M)  - Cash EBITDA increased by 60% and amounted to EUR 6.6M (Q1 2015: EUR 4.2M)  - Profit for the period of EUR 0.1M (Q1 2015: profit of EUR 0.2M)  - Gross ERC at the end of March 2016 was EUR 70.9M (Q1 2015: EUR 63.8M)  - New portfolio acquired in the Czech Republic  - Secured additional debt financing in Q1 to fund the portfolio acquisition  - Pipeline of future transactions remains strong Significant events after the first quarter  - The recent Hungarian transaction closed

Interim report for Q1 2016

Bactiguard started the year by increasing sales of its own product portfolio and delivered approx. 87,600 units, which is more than half of the total volume in 2015. License revenues were lower due to the adjusted order from C.R Bard, but as of March the order situation is back at a stable level. Operating profit was negative, but mayor payments of accounts receivable contributed to a positive cash flow.First quarter (January-March 2016) · During the first quarter, a total of approx. 87,600 (4,650) BIP products were delivered, 100 % of which generated revenues. · Revenues amounted

CXENSE ASA ANNOUNCES FIRST QUARTER RESULTS - Q1 2016

OSLO, NORWAY – 12 MAY, 2016 - CXENSE ASA TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER, WHICH ENDED 31 MARCH, 2016. Highlights: · Q1 2016 revenues of USD 6.3 million, up 61% compared to Q1 2015 revenues of USD 3.9 million. · New Annualized Recurring Revenue (ARR) in Q1 2016 amounted to USD 1.6 million compared to USD 1.5 million in Q1 2015. · In Q1 2016 the company executed the final organizational re-focusing following the 2015 acquisitions. This led to one-off restructuring costs in the quarter, but also a significantly lower adjusted OPEX run-rate into Q2 2016. ·

Tiny hairs in the ear are essential to hearing

[PRESS INVITATION 12 May 2016] Many hearing problems are caused by damage to hair cells in the inner ear. James Hudspeth , Rockefeller University, researches how these cells capture sound and convert it to electrical signals, and how this knowledge can be used to prevent and repair hearing impairment. Professor Hudspeth will soon be coming to the Swedish medical university, Karolinska Institutet to talk more about his work.Reporters are welcome to attend his lecture “Making an Effort to Listen: Mechanical

There are no items matching the current filter
There are no more items matching the current filter
Back to top